Mogelijk gemaakt door Google TranslateTranslate
Latest Press Releases
View all
TimeHeadline
Just nowSFG Quarterly Activities/Appendix 4CCash Flow Report
Just nowBSA Announces On-Market Share Buy-Back
Just nowPlacement
Just nowQ3 FY26 Activities Report and Appendix 4C
Just nowFY26 Q1 Quarterly Activities Report and Appendix 4C

Ligand Pharmaceuticals Inc General Contingent Value Rt

About

Ligand Pharmaceuticals Inc General Contingent Value Rt (PINK:LGNYZ) — investor relations, events, news, and company updates on 6ix.

Latest News

Apr 27 2026
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Apr 22 2026
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
Apr 14 2026
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Mar 26 2026
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
Feb 26 2026
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

Financials

Revenue
$268.09 M

Community Chat

Ask AI

6ix6ix
Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren